CALIWAY BIOPHARMACEUTICALS CO L
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for … Read more
CALIWAY BIOPHARMACEUTICALS CO L (6919) - Total Assets
Latest total assets as of September 2025: NT$9.46 Billion TWD
Based on the latest financial reports, CALIWAY BIOPHARMACEUTICALS CO L (6919) holds total assets worth NT$9.46 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CALIWAY BIOPHARMACEUTICALS CO L - Total Assets Trend (2021–2024)
This chart illustrates how CALIWAY BIOPHARMACEUTICALS CO L’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CALIWAY BIOPHARMACEUTICALS CO L - Asset Composition Analysis
Current Asset Composition (December 2024)
CALIWAY BIOPHARMACEUTICALS CO L's total assets of NT$9.46 Billion consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 70.6% |
| Accounts Receivable | NT$5.18 Million | 0.1% |
| Inventory | NT$2.86 Million | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how CALIWAY BIOPHARMACEUTICALS CO L's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CALIWAY BIOPHARMACEUTICALS CO L's current assets represent 99.3% of total assets in 2024, an increase from 84.9% in 2021.
- Cash Position: Cash and equivalents constituted 70.6% of total assets in 2024, down from 83.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
CALIWAY BIOPHARMACEUTICALS CO L Competitors by Total Assets
Key competitors of CALIWAY BIOPHARMACEUTICALS CO L based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
CALIWAY BIOPHARMACEUTICALS CO L - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CALIWAY BIOPHARMACEUTICALS CO L generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CALIWAY BIOPHARMACEUTICALS CO L is currently not profitable relative to its asset base.
CALIWAY BIOPHARMACEUTICALS CO L - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 114.40 | 149.70 | 149.70 |
| Quick Ratio | 114.31 | 149.65 | 149.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$6.55 Billion | NT$ 9.66 Billion | NT$ 9.66 Billion |
CALIWAY BIOPHARMACEUTICALS CO L - Advanced Valuation Insights
This section examines the relationship between CALIWAY BIOPHARMACEUTICALS CO L's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.36 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 155.3% |
| Total Assets | NT$9.77 Billion |
| Market Capitalization | $4.19 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CALIWAY BIOPHARMACEUTICALS CO L's assets below their book value (0.43 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CALIWAY BIOPHARMACEUTICALS CO L's assets grew by 155.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CALIWAY BIOPHARMACEUTICALS CO L (2021–2024)
The table below shows the annual total assets of CALIWAY BIOPHARMACEUTICALS CO L from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$9.77 Billion | +155.34% |
| 2023-12-31 | NT$3.83 Billion | +210.32% |
| 2022-12-31 | NT$1.23 Billion | +72.97% |
| 2021-12-31 | NT$712.90 Million | -- |